Searched for: in-biosketch:yes
person:morgag04
An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents
Worrillow, Lisa J; Travis, Lois B; Smith, Alexandra G; Rollinson, Sara; Smith, Andrew J; Wild, Christopher P; Holowaty, Eric J; Kohler, Betsy A; Wiklund, Tom; Pukkala, Eero; Roman, Eve; Morgan, Gareth J; Allan, James M
PURPOSE/OBJECTIVE:We sought to determine whether the -6 exon 13 T>C polymorphism in the DNA mismatch repair gene hMSH2 modulates susceptibility to acute myeloid leukemia after therapy and particularly after O(6)-guanine alkylating chemotherapy. We also determined the extent of microsatellite instability (MSI) in therapy-related acute myeloid leukemia (t-AML) as a marker of dysfunctional DNA mismatch repair. EXPERIMENTAL DESIGN/METHODS:Using a novel restriction fragment length polymorphism, verified by direct sequencing, we have genotyped 91 t-AML cases, 420 de novo acute myeloid leukemia cases, and 837 controls for the hMSH2 -6 exon 13 polymorphism. MSI was evaluated in presentation bone marrow from 34 cases using the mononucleotide microsatellite markers BAT16, BAT25, and BAT26. RESULTS:Distribution of the hMSH2 -6 exon 13 polymorphism was not significantly different between de novo acute myeloid leukemia cases and controls, with heterozygotes and homozygotes for the variant (C) allele representing 12.2 and 1.6%, respectively, of the control population. However, the variant (C) hMSH2 allele was significantly overrepresented in t-AML cases that had previously been treated with O(6)-guanine alkylating agents, including cyclophosphamide and procarbazine, compared with controls (odds ratio, 4.02; 95% confidence interval, 1.40-11.37). Thirteen of 34 (38%) t-AML cases were MSI positive, and 2 of these 13 cases were homozygous for the variant (C) allele, a frequency substantially higher than in the control population. CONCLUSIONS:Association of the hMSH2 -6 exon 13 variant (C) allele with leukemia after O(6)-guanine alkylating agents implicates this allele in conferring a nondisabling DNA mismatch repair defect with concomitant moderate alkylation tolerance, which predisposes to the development of t-AML via the induction of DNA mismatch repair-disabling mutations and high-grade MSI. Homozygosity for the hMSH2 variant in 2 of 13 MSI-positive t-AML cases provides some support for this model.
PMID: 12912950
ISSN: 1078-0432
CID: 3649982
Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis
Davies, Faith E; Dring, Ann M; Li, Cheng; Rawstron, Andrew C; Shammas, Masood A; O'Connor, Sheila M; Fenton, James A L; Hideshima, Teru; Chauhan, Dharminder; Tai, Isabella T; Robinson, Elizabeth; Auclair, Daniel; Rees, Karen; Gonzalez, David; Ashcroft, A John; Dasgupta, Ranjit; Mitsiades, Constantine; Mitsiades, Nicholas; Chen, Lan B; Wong, Wing H; Munshi, Nikhil C; Morgan, Gareth J; Anderson, Kenneth C
To define specific pathways important in the multistep transformation process of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) and multiple myeloma (MM), we have applied microarray analysis to PCs from 5 healthy donors (N), 7 patients with MGUS, and 24 patients with newly diagnosed MM. Unsupervised hierarchical clustering using 125 genes with a large variation across all samples defined 2 groups: N and MGUS/MM. Supervised analysis identified 263 genes differentially expressed between N and MGUS and 380 genes differentially expressed between N and MM, 197 of which were also differentially regulated between N and MGUS. Only 74 genes were differentially expressed between MGUS and MM samples, indicating that the differences between MGUS and MM are smaller than those between N and MM or N and MGUS. Differentially expressed genes included oncogenes/tumor-suppressor genes (LAF4, RB1, and disabled homolog 2), cell-signaling genes (RAS family members, B-cell signaling and NF-kappaB genes), DNA-binding and transcription-factor genes (XBP1, zinc finger proteins, forkhead box, and ring finger proteins), and developmental genes (WNT and SHH pathways). Understanding the molecular pathogenesis of MM by gene expression profiling has demonstrated sequential genetic changes from N to malignant PCs and highlighted important pathways involved in the transformation of MGUS to MM.
PMID: 12947006
ISSN: 0006-4971
CID: 3649992
IVIG, aspirin, and Kawasaki disease [Letter]
Morgan, Gareth J; MacLeod, C; Jenkins, J; Stewart, C; Craig, B
PMID: 12970651
ISSN: 0022-3476
CID: 3650002
Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M-CSF (CSF-1) receptor loci
Follows, George A; Tagoh, Hiromi; Lefevre, Pascal; Morgan, Gareth J; Bonifer, Constanze
The c-FMS gene encodes the macrophage colony-stimulating factor receptor (M-CSFR or CSF1-R), which is a tyrosine kinase growth factor receptor essential for macrophage development. We have previously characterized the chromatin features of the mouse gene; however, very little is known about chromatin structure and function of the human c-FMS locus. Here we present a side-by-side comparison of the chromatin structure, histone modification, transcription factor occupancy and cofactor recruitment of the human and the mouse c-FMS loci. We show that, similar to the mouse gene, the human c-FMS gene possesses a promoter and an intronic enhancer element (c-fms intronic regulatory element or FIRE). Both elements are evolutionarily conserved and specifically active in macrophages. However, we demonstrate by in vivo footprinting that both murine and human c-FMS cis-regulatory elements are recognised by an overlapping, but non-identical, set of transcription factors. Despite these differences, chromatin immunoprecipitation experiments show highly similar patterns of histone H3 modification and a similar distribution of chromatin modifying and remodelling activities at individual cis-regulatory elements and across the c-FMS locus. Our experiments support the hypothesis that the same regulatory principles operate at both genes via conserved cores of transcription factor binding sites.
PMCID:219482
PMID: 14530429
ISSN: 1362-4962
CID: 3650012
Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups
Moorman, A V; Roman, E; Cartwright, R A; Morgan, G J
Cytogenetically-defined subgroups of acute myeloid leukaemia have distinct biologies, clinical features and outcomes. Evidence from therapy-related leukaemia suggests that chromosomal abnormalities are also markers of exposure. Our results suggest that the smoking-associated risk for acute myeloid leukaemia is restricted to the t(8;21)(q22;q22) subgroup. This supports the hypothesis that distinct cytogenetic subgroups of acute myeloid leukaemia have separate aetiologies.
PMCID:2746540
PMID: 11857012
ISSN: 0007-0920
CID: 3728102
Age-specific incidence rates for cytogenetically-defined subtypes of acute myeloid leukaemia
Moorman, A V; Roman, E; Cartwright, R A; Morgan, G J
It is generally considered that most cancers arise following the accumulation of several genetic events and that as a consequence its incidence increases with age. We report a cytogenetic subgroup of acute myeloid leukaemia whose incidence is independent of age. This observation indicates that acute myeloid leukaemia can develop via multiple pathways, and underlines the importance of cytogenetics in understanding this disease.
PMCID:2364184
PMID: 11953849
ISSN: 0007-0920
CID: 3728112
Multiple myeloma
Chapter by: Selby, PJ; Morgan, Gareth J
in: Oxford textbook of oncology by Souhami, Robert L (Ed)
Oxford ; New York : Oxford University Press, 2002
pp. ?-?
ISBN: 9780192629265
CID: 3708822
Causative agents in etiology of the myelodysplastic syndromes and the acute myeloid leukemias
Chapter by: Smith, MT; Linet, MS; Morgan, Gareth J
in: The myelodysplastic syndromes : pathobiology and clinical management by Bennett, John M (Ed)
New York : M. Dekker, 2002
pp. ?-?
ISBN: 9780824707828
CID: 3708812
High-dose cyclophosphamide with stem cell rescue for severe rheumatoid arthritis: short-term efficacy correlates with reduction of macroscopic and histologic synovitis [Case Report]
Bingham, Sarah; Veale, Douglas; Fearon, Ursula; Isaacs, John D; Morgan, Gareth; Emery, Paul; McGonagle, Dennis; Reece, Richard; Clague, Roy; Snowden, John A
PMID: 11920422
ISSN: 0004-3591
CID: 3706432
Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch mu region indicates an origin from germinal center B cells
Fenton, James A L; Vaandrager, Jan-Willem; Aarts, Wilhelmina M; Bende, Richard J; Heering, Karel; van Dijk, Martin; Morgan, Gareth; van Noesel, Carel J M; Schuuring, Ed; Kluin, Philip M
With the use of DNA-fiber fluorescent in situ hybridization, a BCL2 protein positive follicular lymphoma with a novel BCL2 breakpoint involving the immunoglobulin heavy chain (IGH) switch mu (S(mu)) region instead of the J(H) or D(H) gene segments was identified. Sequence analysis showed that the genomic breakpoint is localized between the S(mu) region of the IGH complex and the first intron of BCL2. Reverse-transcriptase polymerase chain reaction showed expression of a unique hybrid IGH-BCL2 transcript involving the transcription initiation site I(mu). Sequence analysis of the V(H) region of the functional nontranslocated IGH allele showed multiple shared somatic mutations but also a high intraclonal variation (53 differences in 15 clones), compatible with the lymphoma cells staying in or re-entering the germinal center. This is the first example of a t(14;18) translocation that results from an illegitimate IGH class-switch recombination during the germinal center B-cell stage.
PMID: 11781262
ISSN: 0006-4971
CID: 3706422